Gastric Antisecretory Drug Global Market Report 2025
상품코드:1760536
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 175 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
위산 분비 억제제 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년에는 6.1%의 CAGR로 199억 7,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안 예상되는 성장은 위장 장애 유병률 증가, 노인 인구 증가, 소화기 건강에 대한 인식 증가, 의료 인프라 확대, 패스트푸드 및 가공식품 소비 증가로 인해 발생할 것으로 예상됩니다. 예측 기간 동안 예상되는 주요 동향으로는 NSAIDs의 보급, 항지루약의 OTC 판매 확대, 약물전달 시스템의 기술적 발전, 제네릭 의약품의 가용성 확대, 병용요법 개발의 진전 등을 들 수 있습니다.
위장 장애의 유병률 증가는 위산 분비 억제제 시장의 성장을 견인할 것으로 예상됩니다. 위장 장애는 위, 장 및 관련 기관과 같은 소화관에 영향을 미치며 통증, 복부 팽만감, 배변의 변화와 같은 증상을 유발합니다. 이러한 질병의 증가는 건강에 해로운 식습관, 특히 가공식품의 다량 섭취와 낮은 식이섬유 섭취로 인해 장내 세균총을 교란시켜 소화를 저해하는 데 기인합니다. 위산분비 억제제는 위산과다로 인한 소화관 손상을 예방하는 데 중요한 역할을 합니다. 위산 분비를 억제함으로써 소화기관을 보호하는 점막을 자극과 손상으로부터 보호할 수 있습니다. 예를 들어, 미국 기반 서지 데이터베이스인 ScienceDirect가 2025년 5월에 발표한 보고서에 따르면, 2022년에는 약 2,350만 건의 위내시경 검사가 시행된 것으로 나타났습니다. 이처럼 소화기 질환의 유병률 증가는 위산 분비 억제제 시장의 성장을 크게 촉진할 것으로 예상됩니다.
위산 분비 억제제 시장의 주요 업체들은 보다 장기적인 완화를 제공하기 위해 새로운 분비 억제 화합물과 같은 첨단 제품 개발에 주력하고 있습니다. 이러한 화합물은 특정 세포 경로 및 수용체에 대한 표적 작용을 통해 위산 분비를 감소시키거나 억제하는 방식으로 작용합니다. 예를 들어, 인도에 본사를 둔 아쿠무스(Akumus Drugs and Pharmaceuticals)는 2024년 6월 소화기 환자를 위해 설계된 새로운 제형인 라베프라졸+레보설피리드 SR 캡슐을 출시했습니다. 이 제제는 강력한 위분비 억제 작용을 가지고 위벽 세포의 H+/K+ATPase를 억제하는 라베프라졸 나트륨과 중추성 항도파민 작용 및 구토억제 작용을 하는 레보설피리드를 배합한 제제입니다. 이 캡슐은 장용성 라베프라졸 40mg과 서방형 레보설피리드 75mg을 함유하고 있어 표적화된 장시간 치료 효과를 발휘합니다. 두 가지 작용 기전은 산 억제와 위장관 운동 조절에 모두 작용합니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 위산 분비 억제제 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업 분석
세계의 위산 분비 억제제 시장 : 성장률 분석
세계의 위산 분비 억제제 시장 실적 : 규모와 성장, 2019-2024년
세계의 위산 분비 억제제 시장 예측 : 규모와 성장, 2024-2029년, 2034년
세계의 위산 분비 억제제 전체 시장(TAM)
제6장 시장 세분화
세계의 위산 분비 억제제 시장 : 약물 종류별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
양성자 펌프 억제제(PPI)
H2 수용체 길항제
제산제
프로스타글란딘 유사체
세계의 위산 분비 억제제 시장 : 투여 경로별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
경구
정맥내
국소
세계의 위산 분비 억제제 시장 : 유통 채널별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
병원 약국
소매 약국
온라인 약국
기타 유통 채널
세계의 위산 분비 억제제 시장 : 용도별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
위식도역류질환
소화성궤양
졸링거-엘리슨 증후군
기타 용도
세계의 위산 분비 억제제 시장, 양성자 펌프 억제제(PPI) 종류별 하위 세분화, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
Omeprazole
Esomeprazole
Lansoprazole
Pantoprazole
Rabeprazole
Dexlansoprazole
세계의 위산 분비 억제제 시장, H2 수용체 길항제 종류별 하위 세분화, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
Ranitidine
Famotidine
Cimetidine
Nizatidine
세계의 위산 분비 억제제 시장, 제산제 종류별 하위 세분화, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
수산화마그네슘
탄산칼슘
수산화알루미늄
중탄산나트륨
복합 제산제
세계의 위산 분비 억제제 시장, 프로스타글란딘 유사체 유형별 하위 세분화, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
Misoprostol
Enprostil
제7장 지역별·국가별 분석
세계의 위산 분비 억제제 시장 : 지역별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
세계의 위산 분비 억제제 시장 : 국가별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
위산 분비 억제제 시장 : 경쟁 구도
위산 분비 억제제 시장 : 기업 개요
Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
Bayer AG Overview, Products and Services, Strategy and Financial Analysis
AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
Takeda Pharmaceutical Company Ltd. Overview, Products and Services, Strategy and Financial Analysis
Sun Pharmaceutical Industries Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
Dr. Reddy's Laboratories
Chemo Biological
Spansules Pharmatech Pvt. Ltd.
Phoenix Biologicals Pvt. Ltd.
Centurion Remedies Private Limited
Solitaire Pharmacia Pvt. Ltd.
Shreeji Pharma International
Estrellas Life Sciences Private Limited
3s Corporation
Actiza Pharmaceutical Private Limited
Lark Laboratories
Cytonova Labs International Private Limited
Luckys Pharma Lab Pvt. Ltd.
Lexicare Pharma Pvt. Ltd.
Mustcure Healthcare LLP
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
위산 분비 억제제 시장 2029년 : 새로운 기회를 제공하는 국가
위산 분비 억제제 시장 2029년 : 새로운 기회를 제공하는 부문
위산 분비 억제제 시장 2029년 : 성장 전략
시장 동향에 기반한 전략
경쟁 전략
제36장 부록
ksm
영문 목차
영문목차
A gastric antisecretory drug is a medication intended to reduce the production of gastric acid in the stomach. These drugs act by inhibiting specific pathways or receptors that stimulate acid secretion, thereby lowering the acidity of stomach contents. By maintaining a more neutral pH in the gastric environment, these drugs help protect the stomach lining and support digestive health.
The primary drug classes of gastric antisecretory drugs include proton pump inhibitors (PPIs), H2 receptor antagonists, antacids, and prostaglandin analogs. Proton pump inhibitors (PPIs) work by irreversibly inhibiting the enzyme H+/K+-ATPase in the gastric parietal cells, thereby effectively reducing acid production. These medications can be administered via oral, intravenous, or topical routes and are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and other channels. They are used to treat conditions such as gastroesophageal reflux disease (GERD), peptic ulcer disease, Zollinger-Ellison syndrome, and related disorders.
The gastric antisecretory drug market research report is one of a series of new reports from The Business Research Company that provides gastric antisecretory drug market statistics, including gastric antisecretory drug industry global market size, regional shares, competitors with a gastric antisecretory drug market share, detailed gastric antisecretory drug market segments, market trends and opportunities, and any further data you may need to thrive in the gastric antisecretory drug industry. This gastric antisecretory drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The gastric antisecretory drug market size has grown strongly in recent years. It will grow from $14.87 billion in 2024 to $15.78 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. The growth during the historic period can be attributed to factors such as rising stress levels and sedentary lifestyles, an increase in Helicobacter pylori infections, supportive government healthcare policies, the rise of medical tourism, and the expansion of e-commerce and online pharmacy platforms.
The gastric antisecretory drug market size is expected to see strong growth in the next few years. It will grow to $19.97 billion in 2029 at a compound annual growth rate (CAGR) of 6.1%. The projected growth during the forecast period is driven by the increasing prevalence of gastrointestinal disorders, a growing geriatric population, rising awareness about digestive health, expanding healthcare infrastructure, and higher consumption of fast and processed foods. Key trends expected in the forecast period include the widespread use of NSAIDs, greater over-the-counter (OTC) availability of antisecretory drugs, technological advancements in drug delivery systems, increased availability of generic alternatives, and progress in combination therapy development.
The growing prevalence of gastrointestinal disorders is expected to drive the expansion of the gastric antisecretory drug market. Gastrointestinal disorders affect the digestive tract, including the stomach, intestines, and related organs, causing symptoms such as pain, bloating, and changes in bowel movements. The increase in these disorders is largely attributed to unhealthy dietary habits, particularly high intake of processed foods and low fiber consumption, which disrupt the gut microbiota and impair digestion. Gastric antisecretory drugs play a crucial role in preventing damage to the gastrointestinal tract caused by excessive stomach acid. By reducing acid production, these drugs help protect the protective lining of the digestive system from irritation or injury. For example, a report published in May 2025 by ScienceDirect, a US-based bibliographic database, revealed that around 23.5 million gastrointestinal endoscopies were performed in 2022. As such, the rising prevalence of gastrointestinal disorders is expected to significantly drive the growth of the gastric antisecretory drug market.
Major companies in the gastric antisecretory drug market are focusing on developing advanced products, such as new antisecretory compounds, to offer longer-lasting relief. These compounds work by reducing or inhibiting the secretion of gastric acid through targeted actions on specific cellular pathways or receptors. For example, in June 2024, Akums Drugs and Pharmaceuticals, an India-based company, launched Rabeprazole + Levosulpiride SR Capsules, a new formulation designed for gastrointestinal patients. This formulation combines rabeprazole sodium, a potent antisecretory agent that inhibits the H+/K+ ATPase in gastric parietal cells, with levosulpiride, which has central antidopaminergic and antiemetic effects. The capsule delivers 40 mg of enteric-coated rabeprazole and 75 mg of sustained-release levosulpiride, providing targeted and prolonged therapeutic action. Its dual mechanism of action addresses both acid suppression and gastrointestinal motility regulation.
In June 2022, Glenmark Pharmaceuticals Inc., an India-based pharmaceutical company, acquired approved Abbreviated New Drug Applications (ANDAs) from Wockhardt Limited for an undisclosed amount. This acquisition enables Glenmark to strengthen its presence in the U.S. market by adding key products such as Famotidine, Cetirizine Hydrochloride, Lansoprazole, and Olopatadine Hydrochloride to its portfolio. Wockhardt Limited is a manufacturer of gastric antisecretory drugs based in India.
Major players in the gastric antisecretory drug market are Pfizer Inc., Bayer AG, AstraZeneca plc, Takeda Pharmaceutical Company Ltd., Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, Chemo Biological, Spansules Pharmatech Pvt. Ltd., Phoenix Biologicals Pvt. Ltd., Centurion Remedies Private Limited, Solitaire Pharmacia Pvt. Ltd., Shreeji Pharma International, Estrellas Life Sciences Private Limited, 3s Corporation, Actiza Pharmaceutical Private Limited, Lark Laboratories, Cytonova Labs International Private Limited, Luckys Pharma Lab Pvt. Ltd., Lexicare Pharma Pvt. Ltd., Mustcure Healthcare LLP.
North America was the largest region in the gastric antisecretory drug market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gastric antisecretory drug report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the gastric antisecretory drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The gastric antisecretory drug market consists of sales of mucosal protective agents, digestive enzyme supplements, probiotics for gut health, and controlled-release formulations. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Gastric Antisecretory Drug Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on gastric antisecretory drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for gastric antisecretory drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The gastric antisecretory drug market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Drug Class: Proton Pump Inhibitors (PPIs); H2 Receptor Antagonists; Antacids; Prostaglandin Analogs
2) By Route Of Administration: Oral; Intravenous; Topical
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
4) By Application: Gastroesophageal Reflux Disease; Peptic Ulcer Disease; Zollinger-Ellison Syndrome; Other Applications
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Gastric Antisecretory Drug Market Characteristics
3. Gastric Antisecretory Drug Market Trends And Strategies
4. Gastric Antisecretory Drug Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Gastric Antisecretory Drug Growth Analysis And Strategic Analysis Framework
5.1. Global Gastric Antisecretory Drug PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Gastric Antisecretory Drug Market Growth Rate Analysis
5.4. Global Gastric Antisecretory Drug Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Gastric Antisecretory Drug Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Gastric Antisecretory Drug Total Addressable Market (TAM)
6. Gastric Antisecretory Drug Market Segmentation
6.1. Global Gastric Antisecretory Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Proton Pump Inhibitors (PPIs)
H2 Receptor Antagonists
Antacids
Prostaglandin Analogs
6.2. Global Gastric Antisecretory Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Intravenous
Topical
6.3. Global Gastric Antisecretory Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Other Distribution Channels
6.4. Global Gastric Antisecretory Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Gastroesophageal Reflux Disease
Peptic Ulcer Disease
Zollinger-Ellison Syndrome
Other Applications
6.5. Global Gastric Antisecretory Drug Market, Sub-Segmentation Of Proton Pump Inhibitors (PPIs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Omeprazole
Esomeprazole
Lansoprazole
Pantoprazole
Rabeprazole
Dexlansoprazole
6.6. Global Gastric Antisecretory Drug Market, Sub-Segmentation Of H2 Receptor Antagonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Ranitidine
Famotidine
Cimetidine
Nizatidine
6.7. Global Gastric Antisecretory Drug Market, Sub-Segmentation Of Antacids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Magnesium Hydroxide
Calcium Carbonate
Aluminum Hydroxide
Sodium Bicarbonate
Combination Antacids
6.8. Global Gastric Antisecretory Drug Market, Sub-Segmentation Of Prostaglandin Analogs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Misoprostol
Enprostil
7. Gastric Antisecretory Drug Market Regional And Country Analysis
7.1. Global Gastric Antisecretory Drug Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Gastric Antisecretory Drug Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Gastric Antisecretory Drug Market
8.1. Asia-Pacific Gastric Antisecretory Drug Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Gastric Antisecretory Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Gastric Antisecretory Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Gastric Antisecretory Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Gastric Antisecretory Drug Market
9.1. China Gastric Antisecretory Drug Market Overview
9.2. China Gastric Antisecretory Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Gastric Antisecretory Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Gastric Antisecretory Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Gastric Antisecretory Drug Market
10.1. India Gastric Antisecretory Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Gastric Antisecretory Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Gastric Antisecretory Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Gastric Antisecretory Drug Market
11.1. Japan Gastric Antisecretory Drug Market Overview
11.2. Japan Gastric Antisecretory Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Gastric Antisecretory Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Gastric Antisecretory Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Gastric Antisecretory Drug Market
12.1. Australia Gastric Antisecretory Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Gastric Antisecretory Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Gastric Antisecretory Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Gastric Antisecretory Drug Market
13.1. Indonesia Gastric Antisecretory Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Gastric Antisecretory Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Gastric Antisecretory Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Gastric Antisecretory Drug Market
14.1. South Korea Gastric Antisecretory Drug Market Overview
14.2. South Korea Gastric Antisecretory Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Gastric Antisecretory Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Gastric Antisecretory Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Gastric Antisecretory Drug Market
15.1. Western Europe Gastric Antisecretory Drug Market Overview
15.2. Western Europe Gastric Antisecretory Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Gastric Antisecretory Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Gastric Antisecretory Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Gastric Antisecretory Drug Market
16.1. UK Gastric Antisecretory Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Gastric Antisecretory Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Gastric Antisecretory Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Gastric Antisecretory Drug Market
17.1. Germany Gastric Antisecretory Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Gastric Antisecretory Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Gastric Antisecretory Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Gastric Antisecretory Drug Market
18.1. France Gastric Antisecretory Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Gastric Antisecretory Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Gastric Antisecretory Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Gastric Antisecretory Drug Market
19.1. Italy Gastric Antisecretory Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Gastric Antisecretory Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Gastric Antisecretory Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Gastric Antisecretory Drug Market
20.1. Spain Gastric Antisecretory Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Gastric Antisecretory Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Gastric Antisecretory Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Gastric Antisecretory Drug Market
21.1. Eastern Europe Gastric Antisecretory Drug Market Overview
21.2. Eastern Europe Gastric Antisecretory Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Gastric Antisecretory Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Gastric Antisecretory Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Gastric Antisecretory Drug Market
22.1. Russia Gastric Antisecretory Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Gastric Antisecretory Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Gastric Antisecretory Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Gastric Antisecretory Drug Market
23.1. North America Gastric Antisecretory Drug Market Overview
23.2. North America Gastric Antisecretory Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Gastric Antisecretory Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Gastric Antisecretory Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Gastric Antisecretory Drug Market
24.1. USA Gastric Antisecretory Drug Market Overview
24.2. USA Gastric Antisecretory Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Gastric Antisecretory Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Gastric Antisecretory Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Gastric Antisecretory Drug Market
25.1. Canada Gastric Antisecretory Drug Market Overview
25.2. Canada Gastric Antisecretory Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Gastric Antisecretory Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Gastric Antisecretory Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Gastric Antisecretory Drug Market
26.1. South America Gastric Antisecretory Drug Market Overview
26.2. South America Gastric Antisecretory Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Gastric Antisecretory Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Gastric Antisecretory Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Gastric Antisecretory Drug Market
27.1. Brazil Gastric Antisecretory Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Gastric Antisecretory Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Gastric Antisecretory Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Gastric Antisecretory Drug Market
28.1. Middle East Gastric Antisecretory Drug Market Overview
28.2. Middle East Gastric Antisecretory Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Gastric Antisecretory Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Gastric Antisecretory Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Gastric Antisecretory Drug Market
29.1. Africa Gastric Antisecretory Drug Market Overview
29.2. Africa Gastric Antisecretory Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Gastric Antisecretory Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Gastric Antisecretory Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Gastric Antisecretory Drug Market Competitive Landscape And Company Profiles
30.1. Gastric Antisecretory Drug Market Competitive Landscape
30.2. Gastric Antisecretory Drug Market Company Profiles
30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
30.2.3. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
30.2.4. Takeda Pharmaceutical Company Ltd. Overview, Products and Services, Strategy and Financial Analysis
30.2.5. Sun Pharmaceutical Industries Overview, Products and Services, Strategy and Financial Analysis
31. Gastric Antisecretory Drug Market Other Major And Innovative Companies
31.1. Dr. Reddy's Laboratories
31.2. Chemo Biological
31.3. Spansules Pharmatech Pvt. Ltd.
31.4. Phoenix Biologicals Pvt. Ltd.
31.5. Centurion Remedies Private Limited
31.6. Solitaire Pharmacia Pvt. Ltd.
31.7. Shreeji Pharma International
31.8. Estrellas Life Sciences Private Limited
31.9. 3s Corporation
31.10. Actiza Pharmaceutical Private Limited
31.11. Lark Laboratories
31.12. Cytonova Labs International Private Limited
31.13. Luckys Pharma Lab Pvt. Ltd.
31.14. Lexicare Pharma Pvt. Ltd.
31.15. Mustcure Healthcare LLP
32. Global Gastric Antisecretory Drug Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Gastric Antisecretory Drug Market
34. Recent Developments In The Gastric Antisecretory Drug Market
35. Gastric Antisecretory Drug Market High Potential Countries, Segments and Strategies
35.1 Gastric Antisecretory Drug Market In 2029 - Countries Offering Most New Opportunities
35.2 Gastric Antisecretory Drug Market In 2029 - Segments Offering Most New Opportunities
35.3 Gastric Antisecretory Drug Market In 2029 - Growth Strategies
